Australia markets open in 8 hours 4 minutes
Explore/

Biotech and drug stocks

Biotech and drug stocks

7.52k followers31 symbols Watchlist by Yahoo Finance

Follow this list to discover and track large drug and biotechnology companies.

Curated by Yahoo Finance

Follow this list to discover and track large drug and biotechnology companies. These companies develop speciality drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.

The list includes stocks priced at $5 or more with a three-month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.

This watchlist is similar to a discontinued watchlist called ‘Battling Cancer’.

Background

Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the global financial markets. We bring these insights to you in the form of watchlists.

Find other winning investment ideas with the Yahoo Finance Screener.

How are these weighted?

The stocks in this watchlist are weighted equally.

Performance

WatchlistChange today1-month return1-year returnTotal return
Biotech and drug stocks+0.35%---
^GSPC-0.72%+1.37%+21.52%+5865.61%

31 symbols

SymbolCompany nameLast priceChange% changeMarket timeVolumeAvg vol (3-month)Market cap
LLYEli Lilly and Company842.1001-63.49-7.01%11:56 am GMT-43.61M2.76M758.23B
NVONovo Nordisk A/S127.455-7.96-5.88%11:56 am GMT-45.47M3.85M567.58B
JNJJohnson & Johnson156.68+0.10+0.06%11:56 am GMT-42.83M7.38M377.08B
MRKMerck & Co., Inc.122.905-2.99-2.37%11:56 am GMT-43.28M8.47M311.30B
ABBVAbbVie Inc.175.475+0.21+0.12%11:56 am GMT-42.31M5.48M309.87B
RHHBYRoche Holding AG39.38+0.38+0.97%11:41 am GMT-474.13k2.90M251.16B
AZNAstraZeneca PLC78.425-1.33-1.67%11:56 am GMT-41.34M4.33M243.16B
NVSNovartis AG107.1-4.70-4.20%11:56 am GMT-41.80M1.44M218.53B
AMGNAmgen Inc.336.92+1.25+0.37%11:56 am GMT-4753.84k2.51M180.74B
PFEPfizer Inc.30.415+0.39+1.28%11:56 am GMT-420.78M36.66M172.35B
VRTXVertex Pharmaceuticals Incorporated488.95+0.58+0.12%11:56 am GMT-4522.02k1.17M126.18B
SNYSanofi50.385+0.17+0.35%11:56 am GMT-41.10M2.42M126.07B
REGNRegeneron Pharmaceuticals, Inc.1073.875-11.74-1.08%11:54 am GMT-496.56k440.52k118.33B
GILDGilead Sciences, Inc.74.34+1.04+1.42%11:56 am GMT-42.41M7.69M92.62B
BMYBristol-Myers Squibb Company43.835+0.68+1.59%11:56 am GMT-47.94M15.63M88.86B
ZTSZoetis Inc.181.21-0.41-0.22%11:56 am GMT-4721.13k2.73M82.69B
GSKGSK plc39.62-0.22-0.55%11:56 am GMT-4594.81k3.64M80.79B
MRNAModerna, Inc.122.9-1.15-0.93%11:56 am GMT-4764.23k4.02M47.10B
TAKTakeda Pharmaceutical Company Limited13.555-0.14-1.06%11:55 am GMT-4512.18k1.53M42.97B
HLNHaleon plc8.9599+0.04+0.45%11:55 am GMT-41.05M4.88M40.91B
BIIBBiogen Inc.227.9-0.43-0.19%11:56 am GMT-4207.91k1.11M33.18B
ALNYAlnylam Pharmaceuticals, Inc.233.505-6.51-2.71%11:56 am GMT-4275.39k1.01M29.54B
BAYRYBayer Aktiengesellschaft7.31+0.01+0.14%11:35 am GMT-422.45k1.19M28.73B
ARGXargenx SE466.49+3.08+0.66%11:55 am GMT-4136.28k301.92k28.09B
BNTXBioNTech SE87.15+0.68+0.79%11:56 am GMT-4145.36k750.45k21.00B
ALPMYAstellas Pharma Inc.10.73+0.08+0.75%11:29 am GMT-46.80k323.08k19.27B
TEVATeva Pharmaceutical Industries Limited16.4603+0.08+0.49%11:56 am GMT-45.10M9.95M19.08B
GMABGenmab A/S27.18+0.35+1.30%11:54 am GMT-4263.44k518.61k17.25B
BGNEBeiGene, Ltd.153.95+0.31+0.20%11:54 am GMT-469.08k209.37k17.09B
RPRXRoyalty Pharma plc28.495+0.40+1.41%11:56 am GMT-4577.38k2.74M17.02B
  • Yahoo Finance Video

    Novartis raises 2024 profit guidance, stock slipping though

    Swiss pharmaceutical Novartis (NVS) is raising its full-year profit guidance after topping second quarter earnings and revenue estimates. Novartis' stock is slipping lower Thursday morning despite this positive news. Yahoo Finance senior health reporter Anjalee Khemlani details the pharma giant's outlook on its product pipeline as it positions itself more around sales of its heart failure drug Entresto. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.

  • Yahoo Finance Video

    Novo Nordisk, Eli Lilly fall on data from Roche's weight-loss pill

    Shares of Novo Nordisk (NVO) and Eli Lilly (LLY) are sliding after Roche (ROG.SW, RBO.PA) reported promising early-stage trial data from its weight-loss pill. Yahoo Finance Senior Reporter Anjalee Khemlani breaks down the trial results and how the medication may disrupt the current state of the weight-loss drug market as GLP-1 drugs like Novo Nordisk's Ozempic and Eli Lilly's Mounjaro face record demand. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl

  • Yahoo Finance Video

    Johnson & Johnson CFO outlines Tremfya, Rybrevant launches

    Johnson & Johnson (JNJ) reported strong second-quarter earnings, surpassing estimates for both revenue and profit. The company's revenue reached $22.45 billion, exceeding the expected $22.34 billion, while adjusted earnings per share hit $2.82, above the projected $2.71 per share. JNJ CFO Joe Wolk sits down with Yahoo Finance health reporter Anjalee Khemlani to discuss the pharma giant's new products and growth strategies. Wolk highlights the company's research and development (R&D) efforts, detailing plans to expand the use cases for its antibody Tremfya, including Crohn's disease. Additionally, Wolk discusses the upcoming launch of Rybrevant to treat lung cancer: "That's an area we think we can have a profound impact." "We have at least ten products or platforms that will be $5 billion in peak year sales over the near term," Wolk tells Yahoo Finance, emphasizing the company's robust product pipeline and growth potential. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Angel Smith